Neoplasms

1069 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Narrower: Abdominal Neoplasms 1, ACTH Syndrome, Ectopic 2, Adenocarcinoma 91, Adenocarcinoma of Lung 12, Adenocarcinoma, Bronchiolo-Alveolar 2, Adenocarcinoma, Clear Cell 1, Adenocarcinoma, Mucinous 6, Adenocarcinoma, Papillary 1, Ameloblastoma 2, Astrocytoma 52, Atypical Squamous Cells of the Cervix 1, Carcinoid Tumor 2, Carcinoma 202, Carcinoma in Situ 7, Carcinoma, Acinar Cell 2, Carcinoma, Adenoid Cystic 6, Carcinoma, Basosquamous 1, Carcinoma, Giant Cell 2, Carcinoma, Intraductal, Noninfiltrating 6, Carcinoma, Medullary 1, Carcinoma, Neuroendocrine 3, Carcinoma, Signet Ring Cell 2, Carcinoma, Squamous Cell 72, Carcinoma, Transitional Cell 23, Carcinosarcoma 4, Cholangiocarcinoma 20, Chordoma 3, Craniopharyngioma 2, Cystadenocarcinoma, Mucinous 2, Cystadenocarcinoma, Serous 2, Dermatofibrosarcoma 5, Desmoid Tumors 2, Desmoplastic Small Round Cell Tumor 1, Eccrine Porocarcinoma 1, Endometrial Neoplasms 100, Fallopian Tube Neoplasms 31, Ganglioneuroblastoma 2, Glioblastoma 44, Glioma 116, Gliosarcoma 8, Glomus Tumor 3, Granular Cell Tumor 3, Head and Neck Neoplasms 84, Hemangioendothelioma, Epithelioid 3, Hemangioma 4, Hemangiosarcoma 7, Histiocytoma, Malignant Fibrous 6, Klatskin Tumor 1, Leiomyoma 4, Leiomyosarcoma 11, Leukoplakia 1, Liposarcoma 10, Liposarcoma, Myxoid 5, Lymphangioma, Cystic 1, Lymphoma, Extranodal NK-T-Cell 3, Medulloblastoma 8, Mesothelioma 6, Myoepithelioma 3, Neoplasm Metastasis 122, Neoplasm Recurrence, Local 1, Neoplasm, Residual 16, Neoplasms, Basal Cell 2, Neoplasms, Germ Cell and Embryonal 148, Neoplasms, Unknown Primary 2, Neoplastic Cells, Circulating 3, Neuroblastoma 5, Neuroectodermal Tumors, Primitive 15, Neuroendocrine Tumors 17, Nevus, Pigmented 1, Oligodendroglioma 2, Osteosarcoma 18, Paget Disease, Extramammary 3, Penile Neoplasms 5, Perivascular Epithelioid Cell Neoplasms 2, Pheochromocytoma 2, Prostatic Neoplasms 137, Prostatic Neoplasms, Castration-Resistant 4, Pseudomyxoma Peritonei 3, Rhabdoid Tumor 1, Rhabdomyosarcoma 14, Rhabdomyosarcoma, Alveolar 3, Rhabdomyosarcoma, Embryonal 3, Sarcoma 120, Sarcoma, Clear Cell 3, Sarcoma, Ewing 7, Sarcoma, Synovial 9, Seminoma 2, Soft Tissue Neoplasms 1, Squamous Cell Carcinoma of Head and Neck 65, Thyroid Carcinoma, Anaplastic 4, Uterine Cervical Neoplasms 66, Uterine Neoplasms 168, Vulvar Neoplasms 3

Treatments and conditions

Neoplasms
Treatment and conditionWhere it standsTrials
[11C]AZ1419 3391 + Palacaparib for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[11C]AZ1419 3391 + Palacaparib for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[11C]AZ1419 3391 + Palacaparib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[11C]AZ1419 3391 + Palacaparib + Temozolomide for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[11C]AZ1419 3391 + Palacaparib + Temozolomide for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[11C]AZ1419 3391 + Palacaparib + Temozolomide for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[68Ga]Ga-OncoACP3 for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
130 mCi NYMO32 + 200 mCi NYMO32 + 30 mCi NYMO32 + 50 mCi NYMO32 + 80 mCi NYMO32 for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
186RNL for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
5-FU, Leucovorin, Oxaliplatin, Docetaxel for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
61Cu-NODAGA-LM3 + Comparator for neuroendocrine tumorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
68-Gallium DOTATATE for neuroectodermal tumors, primitivePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
68-Gallium DOTATATE for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha) for penile neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
ABBV-706 + ATEZOLIZUMAB + Alveltamig for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Abemaciclib for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abemaciclib for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abemaciclib + Irinotecan + Temozolomide for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abemaciclib + Irinotecan + Temozolomide for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ABIRATERONE ACETATE + Prednisone for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
abiraterone acetate with prednisone + Tinengotinib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Accelerated Hypofractionated Radiation Therapy for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Acetaminophen (or equivalent) + Dexamethasone (or equivalent) + Histamine H1 Receptor Antagonist + Histamine H2 Receptor Antagonist + MK-2010 + Steroid mouthwash (dexamethasone or equivalent) + Sacituzumab tirumotecan + Epinephrine for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Actinium Ac-225 Vipivotide Tetraxetan for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Acupuncture + Questionnaires for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive Hypofractionated Radiotherapy for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive Hypofractionated Radiotherapy for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive Hypofractionated Radiotherapy for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adebelimab Combined with Apatinib for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adebrelimab for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adebrelimab Combined With Albumin Paclitaxel for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + Nogapendekin Alfa Inbakicept + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AK105 and anlotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aldara - Imiquimod 5% + IDH1R132H-vac for astrocytomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aldara - Imiquimod 5% + IDH1R132H-vac + Vorasidenib hemicitric acid hemihydrate for astrocytomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Allogeneic genetically modified gamma-delta T cells for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Alpelisib for lymphangioma, cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 10 J/cm2) for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 20 J/cm2) for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AMXI-5001:Dose Escalation Phase I + AMXI-5001:Dose Expansion Phase II for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anastrozole placebo + Letrozole placebo + CAMIZESTRANT for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Apalutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Placebo for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen deprivation therapy (ADT) + SRT + REZVILUTAMIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy + Apalutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Receptor Signal Inhibitor (ARSI) + Luteinizing Hormone-Releasing Hormone (LHRH) analog + DOCETAXEL for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen receptor signaling inhibitor (ARSI) + VIR-5500 for prostatic neoplasms, castration-resistantPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen receptor signaling inhibitor (ARSI) + VIR-5500 + DOCETAXEL for prostatic neoplasms, castration-resistantPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
anti-PD1 agent therapy - 1 year for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
anti-PD1 agent therapy - 2 years for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apalutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apatinib+Camrelizumab+SOX + Preoperative Radiotherapy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
APG-157 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for rhabdomyosarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for sarcoma, ewingTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ART6043 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ART6043 + Olaparib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ASP2998 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ASP2998 + Carboplatin + ENFORTUMAB VEDOTIN + PEMBROLIZUMAB for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ASP3082 for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aspirin for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Atezolizumab for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATEZOLIZUMAB + Divarasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATEZOLIZUMAB + Doxorubicin hydrochloride for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATEZOLIZUMAB + Vincristine + Irinotecan + Temozolomide for rhabdomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin + Aspirin for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AUR103 Calcium for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for glioblastomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for gliosarcomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for oligodendrogliomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for glioblastomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for gliosarcomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for oligodendrogliomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Autologous genetically modified gamma-delta T cells for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous hALK.CAR T cells for neuroblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
autologous NK cell plus GD2 antibody for neuroblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Autologous testicular tissue transplantation of prepubertal frozen testicular tissue for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for fallopian tube neoplasmsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for neoplasm metastasisTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Axelopran + pembrolizumab for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Axelopran + pembrolizumab for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Axitinib + AVELUMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD6750 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD6750 + Rilvegostomig for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD8205 and AZD2936 (Rilvegostomig) for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD8205 and AZD5305 (saruparib) + AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD8205 in combination with AZD9574 + AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azenosertib for uterine neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azithromycin + Hydroxychloroquine for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
B1962 for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Balstilimab + evofosfamide + zalifrelimab for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Balstilimab + evofosfamide + zalifrelimab for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Becotatug for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Becotatug Vedotin for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Berzosertib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bevacizumab for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + Divarasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bevacizumab + nivolumab for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bevacizumab + nivolumab + relatlimab for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bevacizumab + nivolumab + rucaparib for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bevonescein (ALM 488) Infusion for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bexmarilimab for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Bezuclastinib for soft tissue neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BHB810 for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
bi-4SCAR GD2/CD70 T cells for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Cystoscopy + Bone Scan + Digital Rectal Examination + MRI-Guided Transurethral Ultrasound Ablation + Multiparametric Magnetic Resonance Imaging + PSMA PET Scan + Questionnaire Administration for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, basosquamousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Multigated Acquisition Scan + Radiologic Imaging Procedure + PIDNARULEX + TRASTUZUMAB DERUXTECAN for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Computed Tomography + Gallium Ga 68 Gozetotide + Positron Emission Tomography + Questionnaire Administration + Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Diagnostic Imaging Testing + Excisional Biopsy + Minimally Invasive Surgery + Pelvic Lymphadenectomy + Questionnaire Administration + Sentinel Lymph Node Mapping + Indocyanine Green for carcinosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN + OMEGA-3-ACID ETHYL ESTERS for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blinatumomab for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
BLINATUMOMAB + Venetoclax for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blood Sample + Cerebrospinal Fluid (CSF) Sample + Chemotherapy Drug, Cancer - Physician's Choice + Non-Investigational Surgical Resection + Radiotherapy (RT) + Tumor Tissue Sample + Temozolomide for neuroectodermal tumors, primitivePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMX-001 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT329 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT329 + CA19-9-targeting monoclonal antibody for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy for osteosarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy + External Beam Radiotherapy (EBRT) + NIMOTUZUMAB + CISPLATIN for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy + External Beam Radiotherapy (EBRT) + placebo for Nimotuzumab + CISPLATIN for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brain surgery + RETIFANLIMAB + RAGIFILIMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brain surgery + SRS + RETIFANLIMAB + RAGIFILIMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Breast Radiotherapy for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Burning Pain + Myofascial Pain + Neuralgia Pain + Orofacial Bone Pain + Persistent Pain for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib + BEVACIZUMAB + ATEZOLIZUMAB + EMACTUZUMAB + RUCAPARIB + SIMLUKAFUSP ALFA + ALECTINIB for neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib + NIVOLUMAB for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib + NIVOLUMAB + IPILIMUMAB for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cadonilimab for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cadonilimab + lenvatinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
camrelizumab; famitinib malate for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capecitabine for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capecitabine for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capecitabine + pembrolizumab for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
capecitabine or 5-FU + Intensity Modulated Radiation Therapy (IMRT) + DOSTARLIMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carbon ion irradiation for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin for vulvar neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + NAB-PACLITAXEL for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + NAB-PACLITAXEL + Cetuximab + CISPLATIN for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Paclitaxel for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin-Paclitaxel for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin-Paclitaxel for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cardio-Oncology Referral for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cemiplimab for penile neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ceralasertib + Olaparib for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + FAMITINIB L-MALATE + CAMRELIZUMAB for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + Hypofractionated external beam radiation + Image-guided brachytherapy for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + MAPK inhibitors + ARSENIC TRIOXIDE for neuroblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy TIP for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy TIP for penile neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating tumor DNA (ctDNA) testing + Datopotamab Deruxtecan for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clinical decision support tool for hemangiomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clinical decision support tool for nevus, pigmentedPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clofutriben for acth syndrome, ectopicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clomiphene Citrate 25mg for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Combination 5-azacytidine and nivolumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Community Treatment for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
concurrent chemotherapy + Definitive hypofractionated intensity-modulated radiation theraphy for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Continuous, hyperfractionated, accelerated radiotherapy(CHART) for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Conventional Surgery + Intensity-Modulated Radiation Therapy + Quality-of-Life Assessment + Trametinib + PEMBROLIZUMAB + DABRAFENIB for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Core Biopsy + Questionnaire Administration + AFIMOXIFENE for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Counseling + Questionnaire Administration + Psilocybin for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CP-383 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CP-383 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CR-002 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CR-002 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CR-002 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CTX-471 + Tovecimig for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide + VINORELBINE for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CYP Cocktail + ZIPALERTINIB for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytokine support + EB-PT-CAR-NK-D + EB-PT-CAR-NK-S + Lymphodepleting chemotherapy for neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
D Vitamin for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dabrafenib and trametinib (combination) for ameloblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dabrafenib, trametinib, nivolumab for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
dabrafenib/trametinib for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dacarbazine for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dalpicilib combined with cetuximab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Daraxonrasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Daraxonrasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Darolutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Datopotamab Deruxtecan for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Definitive radiotherapy for dermatofibrosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for histiocytoma, malignant fibrousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
dendritic cell vaccine therapy + fludeoxyglucose F 18 + laboratory biomarker analysis + NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL + positron emission tomography + FLUDARABINE PHOSPHATE + Cyclophosphamide + ALDESLEUKIN for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone/Dexamethasone acetate + Fludrocortisone/ Fludrocortisone acetate + Rescue Medications + Opevesostat for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Diane-35 + N-METHYL-N-ETHYLTRYPTAMINE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dibotatug for lymphoma, extranodal nk-t-cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Digoxin for neoplastic cells, circulatingPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Disitamab for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Disitamab + ENVAFOLIMAB for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Divarasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Divarasib + Cetuximab for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Divarasib + ERLOTINIB for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Divarasib + Inavolisib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
dMD-002 for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DOCETAXEL + Hydroxychloroquine + Gemcitabine for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dose-escalated radiation therapy for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dose-intensified Accelerated Photon Beam Radiation Therapy for glioblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dose-intensified Photon Beam Radiation Therapy for glioblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dostarlimab for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dostarlimab for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doublet Chemotherapy, Dose-reduced (75%) for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab for neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
DURVALUMAB + Datopotamab Deruxtecan for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + Gem/Cis for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + oleclumab for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + oleclumab for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + oleclumab for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography Test + Doxorubicin hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Educational and Media Intervention for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eflornithine for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EGCG and Quinine Sulfate Vaginal Suppository for atypical squamous cells of the cervixTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ELI-002 2P for cholangiocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELI-002 2P for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eliminating RT to the elective neck for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib + Daraxonrasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib + Daraxonrasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ENABLE Cornerstone for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enfortumab vedotin + pembrolizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enlonstobart for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enoblituzumab for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Enzalutamide + Mevrometostat for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide + Mevrometostat for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide + PEMBROLIZUMAB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide + Tinengotinib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ERAS-601 for chordomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Erdafitinib + cetrelimab for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ETX-19477 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ETX-19477 for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Evorpacept for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exercise Intervention for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exercise Therapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Experimental for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Farletuzumab ecteribulin for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fasudil hydrochloride combined with immunotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE + Temozolomide for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FLUDEOXYGLUCOSE F-18 + PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fluzoparib with Temozolomide for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
FMC-376 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FMT capsule for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical) for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Focal One high intensity focused ultrasound device for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Folfoxiri for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Folfoxiri for neoplastic cells, circulatingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fulvestrant + CDK4/6i + Capivasertib for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Exemestane for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GALLIUM GA-68 GOZETOTIDE for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GALLIUM GA-68 GOZETOTIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
GALUNISERTIB + Enzalutamide for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GCP intratumoral catheter for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Gecacitinib + ZG005 + BEVACIZUMAB for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Gemcitabine + ERLOTINIB + NAB-PACLITAXEL for neoplasms, basal cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Gemcitabine Hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + BEVACIZUMAB + Paclitaxel for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + BEVACIZUMAB + Paclitaxel for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Doxorubicin for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Doxorubicin for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Eribulin for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Eribulin for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + PEMBROLIZUMAB for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + PEMBROLIZUMAB for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + TRASTUZUMAB DERUXTECAN for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + TRASTUZUMAB DERUXTECAN for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 subcutaneous (SC) for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 subcutaneous (SC) for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-108 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-108 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Glucagon-like peptide 1 receptor agonist for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GnRH agonist and Letrozole + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GnRHa + Letrozole for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Green tea leaf for leiomyomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
GSK5471713 for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GT101 + HUMAN INTERLEUKIN-2 for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hafnium oxide for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hafnium Oxide-containing Nanoparticles NBTXR3 + Radiation Therapy for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Haic+tae + tislelizumab + surufatinib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Harm Reduction (E-cigarette switching) for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose Rate Brachytherapy + intra-lesional boost IMRT for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose Rate Brachytherapy + intra-lesional boost IMRT for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Histotripsy for abdominal neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
HRS-1167 tablets + Prednisone Acetate tablets + ABIRATERONE ACETATE for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HS-20093 for osteosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hybrid Palliative Radiation Therapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hypofractionated re-irradiation + MANNITOL + Cetuximab for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IA Carboplatin + IA Caelyx for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IA Carboplatin + IA Etoposide Phosphate for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IBI310 + SINTILIMAB + SURUFATINIB for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
IDH1 peptide vaccine for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
IDH1-vac for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IDH1R132H peptide vaccine for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
IDH1R132H peptide vaccine + AVELUMAB for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Idroxioleate Sodium for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ifinatamab deruxtecan for neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
IMNN-001 for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) for fallopian tube neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
INCA33890 for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
INR101 for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Intensity-modulated radiation therapy (IMRT) for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Internet-Based Intervention + Quality-of-Life Assessment + Questionnaire Administration for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iparomlimab and Tuvonralimab (QL1706) for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ipatasertib + atezolizumab for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ipilimumab for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + Temozolomide for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + Temozolomide for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan hydrochloride + bevacizumab for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
IRINOTECAN HYDROCHLORIDE + BEVACIZUMAB + LEUCOVORIN + Fluorouracil for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma for sarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Irradiation + Surgical resection + PEGFILGRASTIM + Vincristine + ETOPOSIDE + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iscador*P for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iscador*P for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivermectin + Losartan for neoplasmsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Ivonescimab for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivonescimab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ivoximab 20 mg/kg, ivgtt, Q4W + Temozolomide for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Izalontamab Brengitecan for carcinoma, transitional cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
JBI-778 for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
JK-1201I + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
JNJ-101556143 for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
JSKN033 + BEVACIZUMAB + PLATINUM for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ketamine for head and neck neoplasmsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Ketamine Hydrochloride for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ketoprofen for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
KLH-2109+ Leurprorelin acetate Placebo for leiomyomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolarPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolarPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, alveolarPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, embryonalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Larotrectinib for neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib + farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib + farletuzumab ecteribulin for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for liposarcoma, myxoidPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Leucovorin for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lifileucel for histiocytoma, malignant fibrousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lifileucel for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Local Therapy + Standard Therapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Loco-regional radiotherapy for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Loco-regional radiotherapy for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lorigerlimab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Losartan + Paclitaxel for fallopian tube neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Low Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low-Dose Radiation Therapy (LDRT) for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Low-dose Radiotherapy + SINTILIMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lurbinectedin for leiomyosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lurbinectedin for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
LUTETIUM OXODOTREOTIDE LU-177 for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LY3537021 for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M032 + PEMBROLIZUMAB for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
M032 + PEMBROLIZUMAB for gliosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Hypofractionated Radiation Therapy + Positron Emission Tomography + Survey Administration for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Positron Emission Tomography + Stereotactic Body Radiation Therapy + Survey Administration for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Bone Marrow Aspiration + Bone Marrow Biopsy + Clinical Observation + Computed Tomography + Ultrasound + ETOPOSIDE + Doxorubicin hydrochloride + Cyclophosphamide + Carboplatin for ganglioneuroblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, giant cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for chordomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for desmoid tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for perivascular epithelioid cell neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pheochromocytomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for seminomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for vulvar neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, giant cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for chordomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for desmoid tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for perivascular epithelioid cell neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pheochromocytomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for seminomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for vulvar neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine + Carboplatin for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Lumbar Puncture + Radiation Therapy + Dabrafenib Mesylate + TRAMETINIB DIMETHYL SULFOXIDE for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Clinical Observation + Computed Tomography + Ultrasound for ganglioneuroblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Laboratory Biomarker Analysis + Radiation Therapy + Vincristine + Lomustine + Cyclophosphamide + CISPLATIN + Vincristine Sulfate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Multiparametric Magnetic Resonance Imaging + Positron Emission Tomography + Transrectal Ultrasonography Guided Biopsy + Flotufolastat F-18 Gallium for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Maximal surgical resection + Radical radiotherapy + Stupp regimen (oral temozolomide) + THIOTEPA for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mazdutide for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Medium Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Megestrol acetate/Medroxyprogesterone acetate + TAMOXIFEN + Letrozole for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mesna + Paclitaxel + Ifosfamide for neoplasms, germ cell and embryonalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin hydrochloride for medulloblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Methadone for leiomyomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
mFOLFOXIRI for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Migoprotafib + Divarasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mirvetuximab Soravtansine for fallopian tube neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)5
Mirvetuximab Soravtansine for neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mitomycin for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MK-3120 for neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ML-016 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Molecularly matched therapy for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Monotherapy, Dose-reduced (75%) for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
MR-Guided Transurethral US Ablation of Prostate Tissue for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MRI-Guided Transurethral Ultrasound Ablation for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Mupirocin Ointment [Treatment] for head and neck neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
n-dodecyl-B-D-maltoside + Cretostimogene Grenadenorepvec for carcinoma, transitional cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
N17350 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
N17350 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nab-paclitaxel for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nab-paclitaxel + Gemcitabine + VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
NanoKnife System for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Navitoclax for neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Navlimetostat for mesotheliomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Naxitamab for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Near-infrared fluorescence imaging + Indocyanine Green for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Neoadjuvant chemotherapy instead of upfront surgery for neoplastic cells, circulatingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Neoadjuvant Radiation + Surgery + TALIMOGENE LAHERPAREPVEC for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NeuroSAFE procedure for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Niacinamide for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nilotinib and Paclitaxel for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NIMOTUZUMAB + Ivonescimab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nimotuzumab, Benmelstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for glioblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for mesotheliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab & Ipilimumab + Zirdafulven for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
NIVOLUMAB + Catequentinib for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + daratumumab for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + ipilimumab for head and neck neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + ipilimumab for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + ipilimumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + ipilimumab + trabectedin for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + relatlimab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + Relatlimab + CAPECITABINE for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + rucaparib for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NIVOLUMAB + Temozolomide for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NIVOLUMAB + Trametinib + IPILIMUMAB for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab and Ipilimumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NSAI + CDK4/6i + Capivasertib for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nutritional Assessment + Short-Term Fasting + Metformin hydrochloride for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Observation for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Off-label ICI(s) with targeted therapy for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
OK-432 for carcinoma in situPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Olaparib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Olaparib for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Oleclumab for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Olomorasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Olomorasib + PEMBROLIZUMAB + Cetuximab for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Omeprazole 80 mg twice daily for prostatic neoplasms, castration-resistantPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ommaya/VPS + Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OncoSignature + Prexasertib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OncoSignature + Prexasertib + Gemcitabine for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
One or more off-label ICIs alone or with other on-label ICI(s) for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Onfekafusp alfa for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Onfekafusp alfa for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Optune System + PEMBROLIZUMAB + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OR502 + CEMIPLIMAB for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Osilodrostat for acth syndrome, ectopicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Osimertinib for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
OSIMERTINIB + Patritumab Deruxtecan for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Osimertinib + Savolitinib for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Osimertinib + Savolitinib for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OXALIPLATIN + LEUCOVORIN + Fluorouracil for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxcel Q3W for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
paclitaxel combined with platinum for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib for sarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib for sarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Padeliporfin for carcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
Padeliporfin for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
Palacaparib for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Datopotamab Deruxtecan for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Datopotamab Deruxtecan for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Datopotamab Deruxtecan for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Temozolomide for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Temozolomide for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Temozolomide for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Panitumumab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Partial or total penectomy with inguinal and/or pelvic lymph node dissection + PEMBROLIZUMAB + PYRUVATE CARBOXYLASE, MITOCHONDRIAL for penile neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Patritumab Deruxtecan for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PD-1 Inhibitors + Mitoxantrone Hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PD-1antibody plus GEMOX for klatskin tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PD1+ TILs (NUMARZU-001) product infusion for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pegylated liposomal doxorubicin + TOPOTECAN + Paclitaxel for fallopian tube neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for carcinosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for leukoplakiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Pembrolizumab + lenvatinib for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PEMBROLIZUMAB + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab + nesuparib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PEMBROLIZUMAB + Paclitaxel for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + AVELUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + Carboplatin + Olomorasib + PEMBROLIZUMAB + Cetuximab + CISPLATIN for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for carcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for rhabdomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for sarcoma, ewingPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Perillyl alcohol for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
PET/CT + FLUDEOXYGLUCOSE F-18 + [18F]-FAPI-74 for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Petosemtamab for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
PF-08634404 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
PF-08634404 + ENFORTUMAB VEDOTIN for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia] for craniopharyngiomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PIFLUFOLASTAT F-18 for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pirfenidoneone for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo (for Syntocinon) + Oxytocin for craniopharyngiomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Metformin for medulloblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ponsegromab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pravastatin (drug) for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prexasertib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prexasertib + Gemcitabine for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
prifetrastat in combination with fulvestrant for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
prifetrastat monotherapy for 15 days then combination with fulvestrant for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PRL3-zumab for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prophylactic External Beam Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prostate Radiotherapy + Radical Prostatectomy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prostate Radiotherapy + Radical Prostatectomy for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for dermatofibrosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for glomus tumorPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for granular cell tumorPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for hemangioendothelioma, epithelioidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for hemangiosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for histiocytoma, malignant fibrousPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for leiomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for liposarcoma, myxoidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for myoepitheliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for sarcoma, clear cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for glomus tumorPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for granular cell tumorPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for hemangioendothelioma, epithelioidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrousPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for myoepitheliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for glomus tumorPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for granular cell tumorPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for hemangioendothelioma, epithelioidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrousPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for myoepitheliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Psilocybin for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)5
PSMA-guided Salvage Radiation for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Psychotherapy + Survey Administration + Psilocybin for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PUCOTENLIMAB + Becotatug Vedotin for penile neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pulmonary segmentectomy for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Puxitatug Samrotecan for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Puxitatug Samrotecan for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
QLH12016 + Enzalutamide + ABIRATERONE ACETATE for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for dermatofibrosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for histiocytoma, malignant fibrousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Questionnaire Administration + Dordaviprone + Paclitaxel for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Questionnaires + Waitlist Control for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy + OXALIPLATIN + DOCETAXEL + LEVOLEUCOVORIN + PEMBROLIZUMAB + Fluorouracil for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy + Radical Prostatectomy for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
radical surgery + CAMRELIZUMAB + Paclitaxel + CISPLATIN for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiodynamic therapy + AMINOLEVULINIC ACID HYDROCHLORIDE for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + CISPLATIN for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + TRABECTEDIN for leiomyosarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + TRABECTEDIN for liposarcoma, myxoidTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy in painting dose on histoscannographic mapping for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
radium Ra 223 dichloride + Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Olaparib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Regorafenib for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Regorafinib for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Relacorilant + nab-paclitaxel for fallopian tube neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Relugolix for leiomyomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Relugolix for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Reproductive organ sparing radical cystectomy for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rescue medications + Sacituzumab tirumotecan for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rimegepant for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Risvutatug rezetecan (Ris-Rez) for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
RITUXIMAB + LENALIDOMIDE + Acalabrutinib for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Robot-Assisted Radical Prostatectomy + ALLOGENEIC HUMAN AMNION/CHORION MEMBRANE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rocuronium 1.5mg/kg/hr for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rucaparib for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib + NAVITOCLAX for neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
S-1 + Irinotecan for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab + cisplatin for uterine neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab govitecan for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab govitecan for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sacituzumab govitecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sacituzumab tirumotecan for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Savolitinib + Placebo for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Savolitinib + Placebo for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sbrt for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sbrt for neuroendocrine tumorsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Segmentectomy for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selective coverage radiotherapy for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selinexor for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selinexor for rhabdoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selinexor, anti-PD-1 antibody plus Golidocitinib for lymphoma, extranodal nk-t-cellTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Selpercatinib for carcinoma, medullaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sequential cytoreductive intervention for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Serplulimab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SHR-A1811 Injection for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SI-B003 + Izalontamab for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sintilimab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SINTILIMAB + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Siremadlin + PAZOPANIB for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sirolimus for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SOC plus trastuzumab and pembrolizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin + Rilvegostomig for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for gliosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sotorasib for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for mesotheliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for neoplasms, unknown primaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Srs + retifanlimab + ragifilimab for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + Bemarituzumab for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + DEPATUXIZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + NIVOLUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + RAMUCIRUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + TRASTUZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard of Care (SOC) for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard of Care SBRT and ADT + ABIRATERONE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard of Care SBRT and ADT + Atorvastatin + ABIRATERONE for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard of Care Surgery + NIVOLUMAB for head and neck neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Standard of Care Surgery + NIVOLUMAB + IPILIMUMAB for head and neck neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
standardized exercize program + Standardized nutritional program + Whey protein supplement with added leucine and β-hydroxy-β-methylbutyrate (HMB) for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
stereotactic ablative radiotherapy + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
stereotactic ablative radiotherapy + TESTOSTERONE + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Stereotactic Body Radiation Therapy (5 days) + Surgical Resection + PEMBROLIZUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Subventricular Zone radiation for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sugemalimab for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sunitinib for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Surufatinib Combined With Temozolomide and S-1 for neuroendocrine tumorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SXRN Injection for neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 + Becotatug + Enlonstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 + Enlonstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6010 injection + Enlonstobart for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SYS6010 injection + PEMBROLIZUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAGRAXOFUSP + Azacitidine + Venetoclax for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Talazoparib + avelumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
talazoparib plus enzalutamide for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Talimogene Laherparepvec (T-VEC) for carcinoma, squamous cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Talimogene laherparepvec + nivolumab + trabectedin for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tamoxifen for carcinoma, intraductal, noninfiltratingPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tamoxifen for neoplasm recurrence, localPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tarlatamab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Tarlatamab + Temozolomide for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Telesurgery utilizing Microport Medbot Robotic Platform for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Telisotuzumab vedotin for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Telpegfilgrastim for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Temozolomide for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Temozolomide for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Terbium 161- PSMA I&T for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Testosterone for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Therapeutic Intervention for neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tiragolumab and atezolizumab for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tisagenlecleucel for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for mesotheliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for neoplasms, unknown primaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
Tislelizumab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for desmoplastic small round cell tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tki + blinatumomab for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TOCOPHEROL + Pentoxifylline for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Topical application of Periplaneta americana-derived Meilian Fuxin Solution for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Topotecan + toripalimab for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tovecimig for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + DABRAFENIB for ameloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + DABRAFENIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + DABRAFENIB for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib and Nivolumab for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
transarterial radioembolization + CAPECITABINE + Temozolomide for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Transporter Cocktail + ZIPALERTINIB for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trastuzumab deruxtecan for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trastuzumab deruxtecan for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRASTUZUMAB DERUXTECAN + Palacaparib for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRASTUZUMAB DERUXTECAN + Palacaparib for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRASTUZUMAB DERUXTECAN + Palacaparib for prostatic neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRASTUZUMAB DERUXTECAN + Rilvegostomig for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
treatment with focal HIFU for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tremelimumab for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TREMELIMUMAB + Olaparib for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Triptorelin pamoate for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TTP-ICG fluorescent probe for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TULSA Procedure for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tulsa-pro for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
TYRA-300 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TYRA-300 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBAMATAMAB + Ubletamig + SARILUMAB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBAMATAMAB + Ubletamig + SARILUMAB for fallopian tube neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Upifitimab rilsodotin for fallopian tube neoplasmsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Utidelone capsule 35mg/m2/d BID for fallopian tube neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Utidelone capsule 40mg/m2/d BID for fallopian tube neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Utidelone capsule 50mg/m2/d BID for fallopian tube neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Utidelone capsule 75mg/m2/d QD for fallopian tube neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Valacyclovir for head and neck neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vebreltinib for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vinorelbine for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VIR-5500 for prostatic neoplasms, castration-resistantPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
vitamin D 25(OH)D for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
vitamin D 25(OH)D for prostatic neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VLS-1488 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VLS-1488 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for mesotheliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for mesotheliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for adenocarcinoma, clear cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for fallopian tube neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vusolimogene Oderparepvec for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Xaluritamig for prostatic neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Xiaochaihu Granules (Low Dose) for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
XON7 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
XPO1 inhibitor for lymphoma, extranodal nk-t-cellTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Zanzalintinib for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
zevor-cel for carcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for head and neck neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zidesamtinib (NVL-520) for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zipalertinib for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zirdafulven for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zirdafulven + Olaparib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zolbetuximab for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zymosan + α-lactalbumin vaccine for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.